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Abstract
Further synthetic modification of the furan ring of salvinorin A (1), the major active component of
Salvia divinorum, has resulted in novel neoclerodane diterpenes with opioid receptor affinity and
activity. A computational study has predicted 1 to be a reproductive toxicant in mammals and is
suggestive that use of 1 may be associated with adverse effects. We report in this study that
piperidine 21 and thiomorpholine 23 have been identified as selective partial agonists at kappa
opioid receptors. This indicates that additional structural modifications of 1 may provide ligands
with good selectivity for opioid receptors but with reduced potential for toxicity.
Introduction
The neoclerodane diterpene, salvinorin A (1), is the main active component of the
hallucinogenic mint plant Salvia divinorum.1, 2 Lately, salvinorin A - containing products
have become increasingly available and self-administration of these products has been
reported.3–6 Historically, S. divinorum has been used medicinally by the Mazatecs of
Oaxaca, Mexico for several conditions, but its mode of action was only recently discovered.
7 Studies indicate that 1 has high affinity and activity at κ opioid (KOP) receptors, and has
no affinity for the molecular targets of other hallucinogenic substances such 5-HT2, C B1/
CB2, NMDA, or muscarinic receptors.8 Furthermore, 1 appears to have unique properties as
a ligand at KOP receptors, including ultra-high efficacy in particular transduction systems,
and a reduced propensity to cause receptor desensitization.9, 10
A growing number of experimental studies have explored the effects of 1 in animals.11–21
For example, 1 was found to substitute for KOP agonist U69,593 but did not substitute for
DOM in DOM-trained non-human primates.19, 20 This suggests that the hallucinogenic
experience elicited by 1 is qualitatively different than that of classical hallucinogens such as
DOM. In rodents, 1 has been found to decrease striatal dopamine overflow and block the
locomotor effects of cocaine.16, 18 These findings provide further evidence for the potential
utility of 1 and related analogues as stimulant abuse therapeutics.22
It is relatively rare for natural products, such as 1, to have sufficiently attractive ADME/Tox
(Absorption, Disposition, Metabolism, Excretion, and Toxicity) properties to be marketable,
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despite their excellent potency and selectivity. ADME/Tox has become integrated into the
drug discovery process and is a tremendous asset in guiding selection and optimization.23, 24
Thus, the ability to improve these properties by semi- or total synthetic chemistry is
important in drug seeking campaigns.
Generally, furan-containing natural products, such as 1, are of limited medicinal value. This
results from their potential for toxicity after bioactivation.25–27 For instance, previous work
has shown that teucrin A (2), a neoclerodane present in germander (Teucrium chamaedrys
L.; Lamiaceae), has the ability to produce hepatotoxicity.28 This results from the formation
of an enedial formed from the metabolism of the furan ring by cytochrome P450 enzymes
(CYP450s).29, 30 The resulting enedial is then capable of reacting with peptides to form
stable conjugates.29 Using a proteomic analysis, the major targets of 2 were found to be
mitochondrial and ER-associated proteins and enzymes involved in small molecule
metabolism and cell maintenance.30 Aflatoxin B1 (3), a difurano-containing natural product
produced by Aspergillus species, is a known hepatic carcinogen. Bioactivation of aflatoxin
B1 by CYP450s is thought to involve a similar dial intermediate to the one formed from 2.31
As a furan-containing natural product, 1 also has the potential to form reactive metabolites
resulting from bioactivation by CYP450s. This hampers its further development as a
potential stimulant abuse therapeutic.32
One approach to circumventing the potential toxicity of a furan-containing natural product is
to explore different structural replacements for the furan ring. Ideally, these modifications
should have low to no potential for toxicity but retain affinity and activity at opioid
receptors. Previously, we found that modification of the furan ring of 1 resulted in
neoclerodanes that possessed reduced affinity and efficacy at opioid receptors.33–35 These
previous findings, as well as a recent report,36 suggested that additional structural
modifications of 1 may lead to analogues with higher potency and potential utility as drug
abuse medications. Here, we report our efforts to identify furan modified neoclerodanes with
affinity and activity at KOP receptors.
Results and Discussion
Initially, a computational toxicological study (MC4PC, MultiCASE, Inc.) was performed on
1 and three structurally similar compounds (columbin,37 diosbulbin G,38 and salvinorin B2)
identified using the Derwent World Index and Prous Integrity databases. The results of this
investigation found that at pre-clinical endpoints 1 is predicted to be a reproductive toxicant
in mammals (rabbits, rats, and mice). This suggests that 1 may have adverse effects
associated with its use. However, there are few experimentally determined reports on the
toxicological effects of 1. A limited study in mice found that 1 produced no histological
differences in control animals in the liver, spleen, kidney bone marrow, or brain tissue.39
However, more detailed studies on the potential toxicological effects of 1 are warranted.
Given the strong likelihood that the potential adverse effects of 1 are due to the presence of
the furan ring, we sought to find other structural motifs that could potentially mimic the
furan at its binding site. While a model has been proposed for the binding of 1 to the KOP,
40, 41 the binding pocket of 1 will not be known definitively until the structure of a KOP – 1
complex is solved. Given the lack of these published studies, other indirect methods are
needed to more fully elucidate the nature of binding of 1 at the KOP receptor. Our approach
was to systematically change the structure of the position corresponding to the furan ring
and probe its effects on opioid receptor affinity and activity.
We initially targeted amide and ester derivatives due to their relative ease of synthesis,
potential for reduced toxicity, and, likely improved water solubility. Our design strategy
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consisted of two parts: (1) the carbonyl of the amide or ester might participate in a hydrogen
bonding interaction similar to the furanyl oxygen; and (2) enhanced affinity and/or activity
might result from the addition of a suitable group off the amide or ester bond. Our results are
described herein.
Chemistry
The synthesis of analogues 5 – 30 and 34 – 37 is outlined in Schemes 1 and 2. Salvinorin A
(1) was extracted from commercially available S. divinorum leaves as described previously.
42 The treatment of 1 with NaIO4 and a catalytic amount of RuCl3 afforded key intermediate
4.33 The coupling of acid 4 with the appropriate aniline or alkylamine using EDCI in
CH2Cl2 afforded analogues 5 – 30 in 18 – 75 % yield.
The treatment of acid 4 with CDMT and N-methylmorpholine followed by ethanethiol
afforded thioester 31 in 88% yield.43–46 The reduction of 31 with triethylsilane and Pd/C
gave aldehyde 32 in 82% yield.47 Asymmetric allylation of aldehyde 32 was accomplished
in 50% yield with B-allyl-(10S)-(trimethylsilyl)-9-borabicyclo[3.3.2]decane (prepared in situ
from 9-[(1R,2R)-pseudoephedrinyl]-(10S)-(trimethylsilyl)-9-borabicyclo[3.3.2]decane and
allylmagnesium bromide.48 To determine the absolute stereochemistry of alcohol 33a,
mosher ester 33b was prepared in 82% yield using oxalyl chloride and (R)-(+)-α-methoxy-α-
trifluoromethylphenylacetic acid.49 NMR analysis of 33b and its (S)-epimer made from the
S-acid, was not definitive as to the configuration of the stereocenter. Therefore, X-ray
analysis of 33b was conducted and established the correct relative stereochemistry; the
absolute configuration was then assigned using the known stereochemistry for much of the
molecule.
Acylation of 33a with acryloyl chloride under basic conditions gave the corresponding ester
which was then treated with 2nd generation Grubbs catalyst to afford 5,6-dihydro-2H-
pyran-2-one 34 in 23% yield for the two steps.50,51 The reaction of 4 with either (2-
hydroxybenzyl)triphenyl-or (2-thiobenzyl)triphenyl-phosponium bromide afforded the
benzofuran (35) and benzothiophene (36), respectively.52 Finally, coupling of the acid 4
with N-hydroxybenzene-carboximidamide using EDCI followed by cyclization afforded 4-
phenyl-1,3,5-oxadiazole 37.34
Biology
Compounds 1, 5 – 30, and 34 – 37 were then evaluated for affinity at human opioid
receptors using methodology previously described (Table 1).53 As mentioned earlier, we and
others have found previously that modification of the furan ring of 1 resulted in altered
affinity and activity at opioid receptors.33, 34, 36 These findings suggested that further
modification to the furan ring may result in analogues with improved potency and potential
as drug abuse medications. To further elucidate the structure-activity relationships of
neoclerodane diterpenes at opioid receptors, we synthesized an additional series of furan
modified analogues.
Our initial modification was to replace the furan ring in 1 with an anilido group (5). It was
envisioned that the benzene ring would participate in a hydrophobic interaction similar to
the furan ring and the amide group could participate in a hydrogen bonding interaction. This
modification was not well tolerated and affinity was lost at opioid receptors (Ki > 10,000
nM). The reasons for this loss in affinity were not readily apparent. One potential reason for
this loss in affinity was the flexibility of the aromatic ring relative to the amide bond. To
address this issue, we synthesized indoline 6 as a more conformationally restricted analogue
of 5. This change, however, did not enhance affinity suggesting that either the conformation
was not optimal or that alkylation of the aniline portion was not tolerated. Another potential
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reason for the lack of affinity of 5 is the presence of the aromatic ring. Thus, we prepared
cyclohexane 7 and cyclopentane 8. Replacement of the phenyl ring in 5 with these saturated
systems resulted in a greater than 10-fold and 5-fold increase in affinity at KOP receptors,
respectively. The replacement of the phenyl ring with a 3-pyridine (9) was not tolerated.
Recent molecular modeling and site-directed mutagenesis studies have indicated that the
oxygen in the furan ring present in 1 forms a critical hydrogen bond with Y119 at the KOP
receptor.40, 41, 54, 55 This suggested to us that the inclusion of a hydrogen bond acceptor
group to anilide 5 may enhance affinity at KOP receptors. Unfortunately, this design
strategy met with little success. Generally, the addition of a methoxy group to 5 (10 – 16)
did not increase affinity for opioid receptors. Interestingly, 12 and 13 were found to have
weak affinity for MOP and DOP receptors and no affinity for KOPs. To further explore the
role of electronics in the binding of these compounds to opioid receptors, we prepared
brominated analogues 17 – 19. Surprisingly, 17 – 19 possessed affinity at MOP receptors.
This suggests that the furan ring may also have a role in determining the selectivity for
opioid receptors. However, other modifications will need to be explored to further define the
role of the furan ring in opioid receptor selectivity. In addition, these findings suggested that
these compounds, while similar in structure to 1, may be interacting with opioid receptors in
a different manner.
We also explored additional structural modifications of the furan. The replacement of the
furan ring in 1 with a 5,6-dihydro-2H-pyran-2-one (34) was found to greatly reduce affinity
for KOPs. This molecule was prepared as a potential neoclerodane based affinity label.
However, its low affinity for KOPs greatly hampers it potential utility in this capacity. Other
structural modifications may lead to more useful pharmacological tools to better characterize
the interactions of neoclerodanes with opioid receptors. Replacement of the furan with a 2-
benzofuran (35) greatly decreases affinity for KOPs compared to 1. However, this
modification had little effect on MOP affinity but enhanced affinity for DOP receptors.
Interestingly, bioisosteric replacement of the 2-benzofuran (35) with a 2-benzothiophene
(36) resulted in similar affinity for MOPs and DOPs but led to a loss in affinity for KOPs (Ki
> 10,000 nM). Similar results were seen when the 2-benzofuran was replaced with a 4-
phenyl-1,3,5-oxadiazole (37). This is in agreement with recent findings of Beguin et al.36
However, 37 was found to have affinity for MOP receptors (Ki = 1,610 nM).
Given the increased affinity of 7 and 8 for KOPs relative to 5, we explored additional
nonaromatic substitutions. First the cyclohexylamine moeity of 7 was contracted into a
piperidine ring (21). This change resulted in a 9-fold increase in affinity for KOP receptors
relative to 7 (Ki = 140 nM vs. Ki = 1220 nM). Replacement of the piperidine ring with a
pyrrolidine ring (22) resulted in a 9-fold loss in affinity (Ki = 1,210 M vs. Ki = 140 nM).
Given this interesting result, we decided to further probe the role of piperidine ring in 21.
Replacement of piperidine ring with either a morpholine ring (20) or a thiomorpholine ring
(23) was well tolerated but did not further enhance affinity for KOP receptors. Addition of a
4-bromo group to the piperidine ring (24) resulted in a 9-fold loss in affinity. This suggests
that substitution in this position is not well tolerated. However, additional modifications
need to be explored to further substantiate this finding.
Previously, we showed that the tetrahydrofuran analogue of 1 retained high affinity for KOP
receptors.34 Based on this finding, we prepared several additional tetrahydrofurans.
Unfortunately, this strategy also met with little success. The insertion of an amide linkage
(25 – 27) resulted in a loss in affinity at KOP receptors. Surprisingly, 25 was found to have
low affinity DOP receptors (Ki = 3,090 nM). This is interesting because this is the first
report of a neoclerodane with some selectivity for DOPs. Its modest affinity augers for the
identification of other neoclerodanes with enhanced affinity for DOPs. The insertion of an
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ester linkage (28 – 30) was better tolerated but did not result in high affinity agents. The
highest affinity compound in this series identified was bicycle 28 (Ki = 610 nM).
Compounds 21 and 23 were then evaluated for functional activity at KOP receptors using a
[35S]GTP-γ-S assay (Table 2).53 Despite their affinity in the 100 nM range, 21 and 23 were
found to be approximately 100-fold less active than 1 as agonists. However, the replacement
of the furan ring with a piperidino or thiomorpholinocarbonyl group was found to reduce
efficacy at KOP receptors. This suggests that additional structural modifications may lead to
analogues with enhanced activity and reduced efficacy.
Conclusions
In summary, we have evaluated 30 furan ring modified analogues of 1 for opioid receptor
affinity. This manuscript reports the first salvinorin A analogue with some selectivity for
DOP receptors (25). This suggests the likelihood of identifying other diterpenes with this
characteristic from natural sources. Piperidine 21 and thiomorpholine 23 were found to be
selective partial agonists at KOPs. However, they are less potent than 1. Furthermore, this is
the first report to discuss the potential toxicological concerns with the use of 1. Additional
structural modifications of 1 are currently being explored and will be reported in due course.
Experimental section
Unless otherwise indicated, all reagents were purchased from commercial suppliers and are
used without further purification. All melting points were determined on a Thomas–Hoover
capillary melting apparatus and are uncorrected. NMR spectra were recorded on either a
Bruker Avance-300 spectrometer, Bruker DRX-400 with qnp probe and/or a Bruker AV-500
with cryoprobe using δ values in ppm (TMS as internal standard) and J (Hz) assignments
of 1H resonance coupling. High resolution mass spectrometry data was collected on either a
LCT Premier (Waters Corp., Milford, MA) time of flight mass spectrometer or an Agilent
6890N gas chromatograph in conjuction with a Quatro Micro GC mass spectrometer
(Micromass Ltd, Manchester UK). Thin-layer chromatography (TLC) was performed on
0.25 mm plates Analtech GHLF silica gel plates using EtOAc/n-hexanes, 1:1 as the solvent
system. Spots on TLC visualized with phosphomolybdic acid in ethanol. Column
chromatography was performed with Silica Gel (32–63 μ particle size) from Bodman
Industries (Atlanta, GA). Analytical HPLC was carried out on an Agilent 1100 Series
Capillary HPLC system with diode array detection at 254.8 nm on an Agilent Eclipse XDB-
C18 column (4.6 × 150 mm, 5 μm) with isocratic elution in 60% CH3CN/40% H2O at a
flow rate of 5.0 mL/min unless otherwise noted.
General Procedure A
A solution of 4 (1 equiv), appropriate amine or alcohol (1.5 equiv), EDCI (2.5 equiv), HOBt
(2.5 equiv) and Et3N (10 equiv) in CH2Cl2 was stirred at room temperature overnight. The
mixture was then washed with saturated aqueous NaHCO3 (3 × 15 mL), H2O (3 × 15 mL),
and brine (15 mL) and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo




Compound 20 was synthesized from compound 4 using procedure A and morpholine to
afford 0.0510 g (44.4%) as a white solid, mp 128 – 130 °C; 1H NMR (400 MHz, CDCl3) δ
5.25 – 5.14 (m, 2H), 3.82 – 3.72 (m, 5H), 3.71 – 3.60 (m, 4H), 3.50 (t, J = 16.0 Hz, 2H),
2.79 (dd, J = 5.8, 10.9 Hz, 1H), 2.37 2.24 (m, 4H), 2.19 (s, 3H), 2.09 (d, J = 16.5 Hz, 1H),
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1.95 (dd, J = 7.5, 13.6 Hz, 1H), 1.77 (d, J = 12.4 Hz, 1H), 1.71 –1.52 (m, 3H), 1.39 (s, 3H),
1.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 202.23, 171.64, 170.98, 169.79, 167.28, 74.98,
71.27, 66.67, 64.53, 53.26, 51.95, 49.14, 46.20, 42.86, 42.00, 37.72, 37.54, 35.11, 35.10,
30.73, 20.59, 18.17, 17.01, 16.03. HRMS (m/z): [M+Na] calcd for C24H33NO9Na,
502.2055; found, 502.2045. HPLC tR = 3.490 min; purity = 98.69%.
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-
(piperidine-1-carbonyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (21)
Compound 21 was synthesized from 4 using procedure A and piperidine to afford 0.0870 g
(75.0%) as a white solid, mp 188 – 191 °C;1H NMR (300 MHz, CDCl3) δ 5.25 (dd, J =
15.1, 7.1 Hz, 1H), 5.18 – 5.07 (m, 1H), 3.67 (s, 3H), 3.66 (m, 1H), 3.53 –3.23 (m, 3H), 2.84
– 2.67 (m, 1H), 2.47 – 2.19 (m, 5H), 2.12 (s, 3H), 2.08 – 1.92 (m, 2H), 1.83 – 1.40 (m, 9H),
1.34 (s, 3H), 1.04 (d, J = 9.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 202.43, 171.81,
171.50, 169.86, 167.41, 75.12, 71.37, 64.65, 53.28, 51.99, 48.89, 46.87, 43.76, 42.12, 38.07,
37.80, 35.17, 30.85, 26.55, 25.56, 24.47, 20.69, 18.32, 17.18, 16.08. HRMS (m/z): [M+Na]




Compound 23 was synthesized from 4 using procedure A and thiomorpholine to afford
0.0430 g (23.8%) as a white solid, mp 102 – 105 °C. 1H NMR (400 MHz, CDCl3) δ 5.27 –
5.09 (m, 2H), 4.18 – 4.05 (m, 1H), 3.88 (dd, J = 14.4, 4.5 Hz, 1H), 3.76 – 3.58 (m, 5H), 2.83
–2.52 (m, 4H), 2.43 – 2.23 (m, 5H), 2.17 (s, 3H), 2.08 (d, J = 14.2 Hz, 1H), 1.90 (dd, J =
13.4, 7.7 Hz, 1H), 1.66 (ddd, J = 31.6, 25.8, 12.0 Hz, 4H), 1.37 (s, 3H), 1.07 (s, 3H). 13C
NMR (101 MHz, CDCl3) δ 202.40, 171.81, 171.14, 169.96, 167.43, 75.15, 71.59, 64.66,
52.12, 49.29, 48.72, 45.52, 42.16 (2C), 37.88, 35.24 (2C), 30.89, 28.21, 27.47, 20.76, 18.33,
17.17, 16.20. HRMS (m/z): [M+H]+ calcd for C24H34NO8S, 496.2005; found, 496.1985.
HPLC tR = 12.474 min; purity = 98.40%.
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(ethylthiocarbonyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (31)
A solution of 4 (1.16 g, 2.83 mmol), CDMT (1.49 g, 8.49 mmol), and N-methylmorpholine
(1.86 mL, 16.96 mmol) in anhydrous THF (25 mL) was stirred at room temperature for 1 h
under an argon atmosphere. Ethanethiol (1.25 mL, 16.96 mmol) was then added and reaction
was stirred at room temperature for an additional 48 hours. H2O (25 mL) was added and the
resulting mixture was extracted with Et2O (3 × 30 mL). The combined Et2O portion was
washed with saturated NaHCO3 (3 × 20 mL), 2N HCl (3 × 20 mL), and saturated NaCl (3 ×
20 mL) and dried (Na2SO4). The solvent was removed under reduced pressure and the
resulting residue purified by flash column chromatography on silica gel using a mixture of
EtOAc/n-hexanes to afford 1.13 g (88.0% yield) of 31 as a white solid, mp 187 – 191 °C; 1H
NMR (500 MHz, CDCl3) δ 5.18 – 5.11 (m, 1H), 4.97 (dd, J = 7.2, 9.7 Hz, 1H), 3.72 (s, 3H),
2.90 (q, J = 7.4 Hz, 2H), 2.73 (dd, J = 5.4, 11.4 Hz, 1H), 2.62 (dd, J = 7.2, 13.7 Hz, 1H),
2.35 – 2.26 (m, 2H), 2.18 (s, 3H), 2.17 – 2.10 (m, 2H), 2.10 – 2.02 (m, 1H), 1.81 –1.73 (m,
1H), 1.70 – 1.62 (m, 1H), 1.62 – 1.51 (m, 2H), 1.37 (s, 3H), 1.27 (td, J = 2.3, 7.3 Hz, 3H),
1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.81, 199.44, 171.72, 170.08, 170.04, 80.41,
75.01, 64.42, 53.54, 52.24, 50.57, 42.13, 39.54, 37.96, 35.59, 30.85, 23.23, 20.81, 18.33,
16.36, 16.09, 14.54. HRMS (m/z): [M+Na] calcd for C22H30O8SNa, 477.1559; found,
477.1536. HPLC tR = 26.933 min; purity = 98.31%.
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A mixture of 31 (0.700 g, 1.54 mmol), triethylsilane (0.737 mL, 4.62 mmol), and 10%
palladium on carbon (32.7 mg) in CH2Cl2 (25 mL) was stirred at room temperature
overnight under an argon atmosphere. Upon completion, the reaction mixture was filtered
through a pad of Celite and the solvent was removed under reduced pressure. A mixture of
EtOAc/n-hexanes (1:25) (40 mL) was added to the residue. The resulting solid was collected
by filtration and dried to afford 0.498 mg (81.9% yield) of 32 as a white solid, mp 194 – 197
°C; 1H NMR (500 MHz, CDCl3) δ 9.68 (s, 1H), 5.16 (dd, J = 8.6, 11.6 Hz, 1H), 4.89 (dd, J
= 7.2, 9.8 Hz, 1H), 3.73 (s, 3H), 2.75 (dd, J = 5.2, 11.6 Hz, 1H), 2.52 (dd, J = 7.1, 13.7 Hz,
1H), 2.36 – 2.24 (m, 2H), 2.18 (s, 3H), 2.16 – 2.07 (m, 1H), 1.96 (dd, J = 3.1, 11.8 Hz, 1H),
1.78 (dt, J = 3.1, 13.4 Hz, 1H), 1.72 – 1.50 (m, 4H), 1.39 (s, 3H), 1.09 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 201.91, 197.98, 171.69, 170.36, 170.11, 79.71, 75.05, 64.50, 53.52,
52.24, 50.98, 42.16, 37.93, 36.64, 35.39, 30.82, 20.80, 18.35, 16.41, 16.37; HRMS (m/z): [M




A solution of 9-[(1R,2R)-pseudoephedrinyl]-(10S)-(trimethylsilyl)-9-
borabicyclo[3.3.2]decane (0.546 g, 1.47 mmol) in anhydrous Et2O (20 mL) at −78 °C was
treated with allylmagnesium bromide (1.47 mL, 1.47 mmol). The mixture was stirred at
room temperature for 1 h and then cooled to −78 °C. A solution of 32 (0.580 g, 1.47 mmol)
in dry THF (3 mL) was added in a dropwise manner and the solution was warmed to 10 °C
overnight. The solvent was removed under reduced pressure and the residue was redissolved
in acetonitrile (10 mL) and (1R,2R)-(−)-psuedoephedrine (0.243 g) was added. The resulting
mixture was heated at reflux overnight. The solvent was removed under reduced pressure
and CH2Cl2 (5 mL) added and the mixture was cooled to 0 °C in an ice bath. The mixture
was filtered to remove the white precipitate. The filtrate was evaporated to dryness and the
residue was purified by column chromatography (eluent: 30 – 50% EtOAc/n-hexanes) to
afford 0.289 g (50% brsm) of 33a as a clear oil; 1H NMR (300 MHz, CDCl3) δ 5.75 (dq, J =
7.1, 10.1 Hz, 1H), 5.08 (dd, J = 6.8, 13.3 Hz, 3H), 4.36 (ddd, J = 9.1, 12.0, 20.8 Hz, 1H),
3.65 (s, 3H), 3.48 – 3.37 (m, 1H), 2.71 (dd, J = 5.8, 11.0 Hz, 1H), 2.52 (s, 1H), 2.33 (dd, J =
7.9, 14.8 Hz, 2H), 2.23 (t, J = 7.1 Hz, 2H), 2.17 (s, 1H), 2.15 – 2.05 (m, 4H), 2.00 (t, J =
10.0 Hz, 2H), 1.70 (d, J = 7.8 Hz, 1H), 1.54 (dd, J = 10.5, 19.3 Hz, 3H), 1.28 (s, 3H), 1.00
(s, 3H). 13C NMR (75 MHz, CDCl3) δ 202.37, 171.91, 171.77, 170.06, 133.99, 118.55,
78.65, 75.21, 72.57, 64.05, 53.53, 52.04, 50.80, 42.16, 38.53, 38.18, 37.80, 34.96, 30.89,





33b was prepared in 82% from 33a and (R)-(+)-α-methoxy-α-trifluoromethylphenylacetic
acid using previously described methods.491H NMR (300 MHz, CDCl3) δ 7.65 – 7.52 (m,
2H), 7.52 – 7.39 (m, 3H), 5.79 – 5.59 (m, 1H), 5.21 – 5.02 (m, 2H), 5.01 – 4.88 (m, 1H),
4.75 (td, J = 6.9, 0.9 Hz, 1H), 4.55 – 4.44 (m, 1H), 3.73 – 3.65 (m, 3H), 3.54 (t, J = 5.4 Hz,
3H), 2.64 – 2.48 (m, 3H), 2.31 – 2.15 (m, 2H), 2.15 – 2.06 (m, 4H), 2.01 – 1.85 (m, 2H),
1.62 – 1.51 (m, 1H), 1.36 (ddt, J = 11.5, 6.7, 5.7 Hz, 1H), 1.30 – 1.08 (m, 6H), 0.88 (s,
3H). 13C NMR (75 MHz, CDCl3) δ 201.98, 171.74, 171.01, 170.09, 166.03, 133.66, 131.97,
129.83 (2C), 128.81 (2C), 127.41, 120.14, 83.78, 76.60, 75.00, 74.80, 63.73, 56.37, 53.19,
52.19, 49.80, 41.99, 37.91, 37.75, 34.76, 34.62, 30.85, 29.86, 20.73, 18.26, 16.16, 14.99.
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A solution of 33a (0.099 g, 0.227 mmol), acryloyl chloride (0.55 mL, 6.80 mmol), NEt3
(0.95 mL, 6.80 mmol), and a catalytic amount of DMAP in CH2Cl2 (10 mL) was stirred at
room temperature overnight. The solvent was removed under recude pressure and the
residue was purified by column chromatography to afford 0.045 g of the corresponding
acrylate which was used with out further purification. A solution of the acrylate and 2nd
generation Grubb’s catalyst (10 mol%) in CH2Cl2 (10 mL) was heated at reflux overnight
under an argon atmosphere. The solvent was removed under reduced pressure and the
residue was purified by column chromatography (eluent: 50% EtOAc/n-hexanes) to afford
0.0245 g (57.6%) of 34 as a white solid, mp > 250 °C; 1H NMR (300 MHz, CDCl3) δ 7.05 –
6.87 (m, 1H), 6.03 (dd, J = 9.8, 2.4 Hz, 1H), 5.22 – 5.04 (m, 1H), 4.55 (dd, J = 11.3, 6.2 Hz,
1H), 4.32 (dd, J = 13.0, 3.3 Hz, 1H), 3.72 (s, 3H), 3.09 – 2.91 (m, 1H), 2.77 (dd, J = 11.1,
5.6 Hz, 1H), 2.38 – 2.08 (m, 9H), 1.95 (t, J = 12.2 Hz, 1H), 1.84 – 1.50 (m, 4H), 1.35 (s,
3H), 1.06 (s, 3H). 13C NMR (75 MHz, DMSO) δ 202.55, 171.81, 171.05, 170.01, 163.54,
145.84, 120.99, 77.60, 75.93, 75.36, 63.96, 53.59, 52.13, 50.56, 42.30, 38.11, 37.12, 35.05,
30.95, 26.01, 20.73, 18.31, 16.32, 15.24. HRMS (m/z): [M+Na] calcd for C24H30O9Na,
485.1787; found, 485.1769. HPLC tR = 19.918 – min; purity = 100%.
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(benzofuran-2-yl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (35)
A solution of 4 (0.200 g, 0.487 mmol), 2-chloro-4,6-dimethoxytriazine (0.086 g, 0.487
mmol), and NEt3 (0.07 mL, 0.487 mmol) in CH2Cl2 (4 mL) was stirred at room temperature
for 1 h. (2-Hydroxybenzyl)triphenylphosphonium bromide (0.220 g, 0.487 mmol), NEt3
(0.21 mL, 1.46 mmol) and toluene (10 mL) were added and the resulting mixture was heated
at reflux overnight. Removal of the solvent under reduced pressure gave a crude residue that
was purified by flash column chromatography (eluent: 25% EtOAc/n-hexanes) to yield
0.0610 g (26%) of 35 as a white solid, mp 192 – 196 °C (dec); 1H NMR (300 MHz, CDCl3)
δ 7.55 (d, J = 7.4 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.35 – 7.17 (m, 2H), 6.71 (s, 1H), 5.66
(dd, J = 11.3, 5.7 Hz, 1H), 5.15 (t, J = 10.0 Hz, 1H), 3.73 (s, 3H), 2.85 – 2.71 (m, 1H), 2.57
(dd, J = 13.4, 5.7 Hz, 1H), 2.38 – 2.09 (m, 8H), 1.99 (dd, J = 24.3, 11.8 Hz, 1H), 1.86 – 1.55
(m, 3H), 1.49 (s, 3H), 1.10 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 202.15, 171.76, 170.85,
170.12, 155.35, 153.94, 127.74, 125.19, 123.27, 121.67, 111.59, 105.42, 75.25, 72.52,
64.31, 53.77, 52.20, 51.25, 42.32, 40.60, 38.32, 35.64, 30.97, 20.76, 18.39, 16.53, 15.40.
HRMS (m/z): [M+H]+ calcd for C27H30O8, 482.1941; found, 482.1945. HPLC tR = 10.606
min; purity = 98.10%.
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(benzo[b]thiophen-2-yl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (36)
A solution of 4 (0.200 g, 0.487 mmol), 2-chloro-4,6-dimethoxytriazine (0.086 g, 0.487
mmol), and NEt3 (0.07 mL, 0.487 mmol) in CH2Cl2 (4 mL) was stirred at room temperature
for 1 h. 2-(Mercaptobenzyl)triphenylphoshonium bromide (0.227 g, 0.487 mmol), and N-
methylmorpholine (0.16 mL, 1.46 mmol) and toluene (10 mL) were added and the resulting
mixture was heated at reflux overnight. Removal of the solvent under reduced pressure gave
a crude residue that was purified by flash column chromatography (eluent: 20% EtOAc/n-
hexanes) to yield 0.0846 g (35%) of 36 as a white solid, mp 223 – 225 °C; 1H NMR (500
MHz, CDCl3) δ 7.83 – 7.78 (m, 1H), 7.74 – 7.70 (m, 1H), 7.37 – 7.30 (m, 2H), 7.23 (s, 1H),
5.92 – 5.79 (m, 1H), 5.19 – 5.09 (m, 1H), 3.73 (s, 3H), 2.83 – 2.64 (m, 2H), 2.35 – 2.27 (m,
2H), 2.22 – 2.11 (m, 6H), 1.84 – 1.74 (m, 2H), 1.72 – 1.58 (m, 2H), 1.50 (s, 3H), 1.13 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 201.99, 171.54, 170.60, 169.97, 143.65, 139.34,
139.04, 124.71, 124.55, 123.84, 122.43, 121.40, 75.13, 75.00, 64.04, 53.52, 52.01, 51.27,
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44.52, 42.10, 38.04, 35.76, 30.75, 20.58, 18.14, 16.39, 15.40. HRMS (m/z): [M+H]+ calcd
for C27H31O7S, 499.1791; found, 499.1777. HPLC tR = 12.324 min; purity = 100%.
X-Ray Crystallographic Study of 33b
Colorless crystals of C33H39F3O10 are, at 100(2) K, monoclinic, space group P21 -C22 (No.
4) with a = 6.6372(4) Å, b = 18.637(1) Å, c = 12.6435(8) Å, β = 93.235(1)°, V = 1561.5(2)
Å3 and Z = 2 molecules {dcalcd = 1.388 g/cm3; μa(MoKα) = 0.113 mm−1}. A full
hemisphere of diffracted intensities (1850 10-second frames with an ω scan width of 0.30°)
was measured for a single-domain specimen using graphite-monochromated MoKα
radiation (λ= 0.71073 Å; fine-focus sealed x-ray tube) on a Bruker SMART APEX CCD
Single Crystal Diffraction System. A total of 18602 integrated reflection intensities having
2θ((MoKα)<61.00° were produced using the Bruker program SAINT; 9099 of these were
unique and gave Rint = 0.048 with a coverage which was 98.6% complete. The data were
corrected empirically for variable absorption effects using equivalent reflections. The Bruker
software package SHELXTL was used to solve (direct methods) and refine (weighted full-
matrix least-squares) the structure with Fo2 data.
The three ethylenic hydrogens were located from a difference Fourier and included in the
structural model as independent isotropic atoms. The remaining hydrogen atoms were
included in the structural model as idealized atoms (assuming sp2- or sp3-hybridization of
the carbon atoms and C-H bond lengths of 0.95 – 1.00 Å) with isotropic thermal parameters
fixed at values 1.2 (nonmethyl) or 1.5 (methyl) times the equivalent isotropic thermal
parameter of the carbon atom to which they are covalently bonded. The final structural
model incorporated anisotropic thermal parameters for all nonhydrogen atoms and isotropic
thermal parameters for all hydrogen atoms. A total of 432 parameters were refined using 1
restraint and 9099 data. Final agreement factors at convergence are: R1(unweighted, based
on F) = 0.045 for 8245 independent absorption-corrected “observed” reflections having
2θ(MoKα)<61.00° and I>2σ(I); R1(unweighted, based on F) = 0.049 and wR2(weighted,
based on F2) = 0.109 for all 9099 independent absorption-corrected reflections having
2θ(MoKα)<61.00°. The final difference map had maxima and minima of 0.51 and −0.22 e−/
Å3, respectively. The Flack parameter [0.0(4)] did not allow the absolute configuration to be
established directly from the X-ray analysis and this was assigned using the known
stereochemistry for much of the molecule. Atomic coordinates for compound 33b have been
deposited with the Cambridge Crystallographic Data Centre (deposition number CCDC
723548). Copies of the data can be obtained, free of charge, on application to CCDC, 12
Union Road, Cambridge, CB2, 1EZ, UK [fax, +44(0)-1223-336033; e-mail,
deposit@ccdc.cam.ac.uk].
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Results from the X-ray analysis on 33b drawn from the experimentally determined
coordinates.
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Reagents and conditions: (a) NaIO4, RuCl3•3H2O, CH3CN/CCl4/H2O; (b) Appropriate
amine or alcohol, EDCI, HOBt, Et3N, CH2Cl2
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Reagents and conditions: (a) CDMT, NMM, EtSH, CH2Cl2, 88%; (b) Pd/C, Et3SiH,
CH2Cl2, 82%; (c) 9-(1R, 2R-pseudoephedrinyl)-(10S)-(trimethylsilyl)-9-
borabicyclo[3.3.2]decane, allylMgBr, Et2O; (d) 1. (R)-(+)-α-Methoxy-α-
trifluoromethylphenylacetic acid, oxalyl chloride, benzene; 2. DMAP, NEt3, CH2Cl2, 82%;
(e) acryloyl chloride, DMAP, Et3N, CH2Cl2, 40%; (f) Grubbs II, CH2Cl2, 58%; (g)
Appropriate Wittig reagent; (h) 1. EDCI, C6H5C(NH2)=NOH, CH2Cl2; 2. Toluene, heat
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Table 1
Opioid receptor binding affinity for compounds 1, 5 – 30, and 34 – 37.53
Cmpd
Ki ± SD, nMa
[3H]DAMGO (MOP) [3H]DADLE (DOP) [3H]U69,593 (KOP)
1 1370 ± 130 >10,000 7.4 ± 0.7
5 >2,800 >4,700 >10,000
6 >2,800 >4,700 >10,000
7 >2,800 >4,700 1,930 ± 220
8 >2,800 >4,700 4,060 ± 280
9 >10,000 >10,000 >10,000
10 >10,000 >10,000 >10,000
11 >10,000 >10,000 >10,000
12 2,490 ± 80 3,690 ± 330 > 10,000
13 2,150± 140 3,200 ± 390 8,290 ± 670
14 >10,000 >10,000 >10,000
15 >10,000 >10,000 >10,000
16 >10,000 >10,000 >10,000
17 1,630 ± 100 > 10,000 7,580 ± 720
18 1,610 ± 80 > 10,000 > 10,000
19 1,570 ± 90 2,600 ± 220 7,280 ± 400
34 >10,000 >10,000 8,060 ± 720
35 1,900 ± 90 3,380 ± 240 2,340 ± 120
36 1,510 ± 100 3,650 ± 260 >10,000
37 1,610 ± 70 2,840 ± 180 >10,000
20 >10,000 >10,000 230 ± 20
21 >10,000 >10,000 140 ± 10
22 >10,000 >10,000 1,210 ± 80
23 980 ± 70 >3,000 160 ± 10
24 >3,000 >3,000 1,250 ± 130
25 >10,000 3,090 ± 220 >10,000
26 >10,000 >10,000 >10,000
27 >10,000 >10,000 >10,000
28 > 10,000 3,360 ± 340 610 ± 30
29 >10,000 >10,000 2,980 ± 240
30 >10,000 >10,000 2,190 ± 300
Receptor binding was performed in CHO cells which express the human MOP, DOP or KOP receptors. All results are n = 3.
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Table 2
Opioid receptor activity for 1, 21, and 23.
Cmpd KOP ED50a KOP Emaxb
1 41 ± 6 124 ± 6
21 5110 ± 1800 85 ± 13
23 3780 ± 970 57 ± 6
U50,488H 27 ± 6 100
a
ED50 = Effective dose for 50% maximal response;
b
Emax is % which compound stimulates binding compared to (−)-U50,488 (500 nM) at KOP receptors.
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